Full-Time
Healthcare technology using AI for patient outcomes
No salary listed
Senior, Expert
Company Historically Provides H1B Sponsorship
Remote in USA + 1 more
More locations: Philadelphia, PA, USA
Job can be performed in Philadelphia, PA or remotely.
Get referrals →
You have ways to get a Tempus referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 8 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide actionable insights, helping physicians make informed treatment decisions and identify gaps in patient care. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive data analysis with a focus on precision medicine, aiming to improve healthcare delivery and drug development.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Relocation Assistance
Company Equity
Performance Bonus
NewEdge Advisors LLC invests $49,000 in Tempus AI, Inc. (NASDAQ:TEM).
Valued at a market cap today of $9.2 billion, Tempus AI stock has surged around 47% since its initial public offering in June 2024.
Tempus AI has entered into strategic partnerships with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology.
Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs.
Tempus AI, Inc, a technology company leading the adoption of AI to advance precision medicine and patient care, announced the launch of the Tempus Advisory Board.